Design Source Inc (NVIV) 2.1600 $NVIV
New medical chief at InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:23AM CST
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
Business Wire - Mon Feb 09, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company.
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board
Business Wire - Thu Feb 05, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo's Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.
InVivo Therapeutics: Long Idea Playing Out With Room To Run
JMY Investments - at Seeking Alpha - Mon Feb 02, 2:01PM CST
InVivo Therapeutics Announces $12 Million Registered Direct Offering
Business Wire - Thu Jan 29, 7:02AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company's common stock in a registered direct offering.
InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
Business Wire - Thu Jan 22, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.
First patient responds well to InVivo Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:37AM CST
InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold
Business Wire - Wed Jan 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced a three-month update for the first subject in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in subjects with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the subject on October 14, 2014 at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ by Dr. Nicholas Theodore, Chief of Spinal Surgery.
InVivo Therapeutics Announces Reopening of Enrollment for Ongoing Pilot Trial
Business Wire - Fri Jan 09, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. To date, there have been no reported serious safety events with the study's first subject, and InVivo has been cleared by the Data Safety Monitoring Board (DSMB) to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial.
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial
Business Wire - Tue Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced approval by the U.S. Food and Drug Administration (FDA) for an expedited enrollment plan for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Under the new plan, barring significant safety issues, InVivo will submit two months of safety data to the FDA for the first subject enrolled in October, and will then open enrollment for the second subject in mid-January (about three months after the first subject was enrolled). Upon enrollment of the second subject, InVivo will submit to the FDA one month of safety data for that subject together with the previous subject's data; concurrent enrollment for the remaining three subjects will then begin (about two months after the second subject is enrolled). There will be no additional mandatory holds between enrollment of the final three subjects. This differs from the previous plan, which required a mandatory three-month hold between sequential enrollment of each of the five subjects.
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Tue Nov 25, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the University of Pittsburgh Medical Center (UPMC) Presbyterian in Pittsburgh, PA as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). UPMC is the largest non-governmental employer in Pennsylvania (with more than 62,000 employees) and operates more than 20 academic, community, and specialty hospitals and 400 outpatient sites. David Okonkwo, MD, PhD, is the Director of Neurotrauma and Director of Scoliosis and Spinal Deformity at UPMC Presbyterian and Associate Professor of Neurological Surgery and Clinical Director of the Brain Trauma Research Center at the University of Pittsburgh. Dr. Okonkwo will be the study's Principal Investigator at that site.
Can InVivo Therapeutics Holdings (NVIV) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:35AM CST
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NVIV’s earnings for the coming quarter and year.
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Fri Nov 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Oregon Health & Science University (OHSU) in Portland, OR is the fifth clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). OHSU is a nationally prominent research university and Oregon's only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study's Principal Investigator at that site.
Medical Device Makers Are Cheering After Latest Victory from GOP
ACCESSWIRE - Fri Nov 14, 10:15AM CST
CORAL GABLES, FL / ACCESSWIRE / November 14, 2014 / For Democrats, the "wounds" are still fresh. A new GOP senate now rules "the Hill" and amidst the fog of uncertainty for some key decisions has arisen one clear standout, which is Obamacare (The Affordable Care Act); more specifically the tax it placed on medical devices. See, the Affordable Care Act imposes a 2.3% excise tax on the sale of medical devices, which in most cases is one of the highest effective tax rates of nearly any industry in the world...and go figure, the US is the only country to impose such a tax on medical devices. In the end, it seems like it has come down to jobs or specifically the ones that have been lost because of the tax. In fact according to the Advanced Medical Technology Association, the Medical Device Tax has cost the industry about 14,000 jobs and prevented the creation of nearly 20,000 more. Now the rise for repeal has begun to echo on Capitol Hill from both parties and in turn, the market has reacted.
InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST
STEM: 1.09 (-0.01), AST: 3.85 (+0.13), CUR: 3.41 (+0.13)
InVivo Therapeutics names Ann Merrifield to board
M2 - Wed Nov 12, 7:13AM CST
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) disclosed on Tuesday the addition of Ann Merrifield to its board of directors.
Barrow Neurosurgeons Implant the World's First Scaffold into a Patient's Spinal Cord
PR Newswire - Tue Nov 11, 1:00PM CST
Performed last month, the surgery involves inserting a bioresorbable scaffolding implant to act as a bridge across the gap of the injured section of the cord in an attempt to help the spinal cord heal. This first case is part of a pilot study to measure the clinical safety of the implanted device developed by InVivo Therapeutics Holdings Corp. If proven successful, surgeons believe the new technique could become a standard protocol in the treatment of acute spinal cord injury.
New medical chief at InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:23AM CST
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
Business Wire - Mon Feb 09, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC, a life sciences consulting company.
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board
Business Wire - Thu Feb 05, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chairman of InVivo's Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.
InVivo Therapeutics: Long Idea Playing Out With Room To Run
JMY Investments - at Seeking Alpha - Mon Feb 02, 2:01PM CST
InVivo Therapeutics Announces $12 Million Registered Direct Offering
Business Wire - Thu Jan 29, 7:02AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company's common stock in a registered direct offering.
InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
Business Wire - Thu Jan 22, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.
First patient responds well to InVivo Spinal Scaffold
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:37AM CST
InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold
Business Wire - Wed Jan 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced a three-month update for the first subject in the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in subjects with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the subject on October 14, 2014 at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ by Dr. Nicholas Theodore, Chief of Spinal Surgery.
InVivo Therapeutics Announces Reopening of Enrollment for Ongoing Pilot Trial
Business Wire - Fri Jan 09, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. To date, there have been no reported serious safety events with the study's first subject, and InVivo has been cleared by the Data Safety Monitoring Board (DSMB) to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial.
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial
Business Wire - Tue Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced approval by the U.S. Food and Drug Administration (FDA) for an expedited enrollment plan for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Under the new plan, barring significant safety issues, InVivo will submit two months of safety data to the FDA for the first subject enrolled in October, and will then open enrollment for the second subject in mid-January (about three months after the first subject was enrolled). Upon enrollment of the second subject, InVivo will submit to the FDA one month of safety data for that subject together with the previous subject's data; concurrent enrollment for the remaining three subjects will then begin (about two months after the second subject is enrolled). There will be no additional mandatory holds between enrollment of the final three subjects. This differs from the previous plan, which required a mandatory three-month hold between sequential enrollment of each of the five subjects.
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Tue Nov 25, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the University of Pittsburgh Medical Center (UPMC) Presbyterian in Pittsburgh, PA as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). UPMC is the largest non-governmental employer in Pennsylvania (with more than 62,000 employees) and operates more than 20 academic, community, and specialty hospitals and 400 outpatient sites. David Okonkwo, MD, PhD, is the Director of Neurotrauma and Director of Scoliosis and Spinal Deformity at UPMC Presbyterian and Associate Professor of Neurological Surgery and Clinical Director of the Brain Trauma Research Center at the University of Pittsburgh. Dr. Okonkwo will be the study's Principal Investigator at that site.
Can InVivo Therapeutics Holdings (NVIV) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:35AM CST
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NVIV’s earnings for the coming quarter and year.
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Fri Nov 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Oregon Health & Science University (OHSU) in Portland, OR is the fifth clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). OHSU is a nationally prominent research university and Oregon's only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study's Principal Investigator at that site.
Medical Device Makers Are Cheering After Latest Victory from GOP
ACCESSWIRE - Fri Nov 14, 10:15AM CST
CORAL GABLES, FL / ACCESSWIRE / November 14, 2014 / For Democrats, the "wounds" are still fresh. A new GOP senate now rules "the Hill" and amidst the fog of uncertainty for some key decisions has arisen one clear standout, which is Obamacare (The Affordable Care Act); more specifically the tax it placed on medical devices. See, the Affordable Care Act imposes a 2.3% excise tax on the sale of medical devices, which in most cases is one of the highest effective tax rates of nearly any industry in the world...and go figure, the US is the only country to impose such a tax on medical devices. In the end, it seems like it has come down to jobs or specifically the ones that have been lost because of the tax. In fact according to the Advanced Medical Technology Association, the Medical Device Tax has cost the industry about 14,000 jobs and prevented the creation of nearly 20,000 more. Now the rise for repeal has begun to echo on Capitol Hill from both parties and in turn, the market has reacted.
InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST
STEM: 1.09 (-0.01), AST: 3.85 (+0.13), CUR: 3.41 (+0.13)
InVivo Therapeutics names Ann Merrifield to board
M2 - Wed Nov 12, 7:13AM CST
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) disclosed on Tuesday the addition of Ann Merrifield to its board of directors.
Barrow Neurosurgeons Implant the World's First Scaffold into a Patient's Spinal Cord
PR Newswire - Tue Nov 11, 1:00PM CST
Performed last month, the surgery involves inserting a bioresorbable scaffolding implant to act as a bridge across the gap of the injured section of the cord in an attempt to help the spinal cord heal. This first case is part of a pilot study to measure the clinical safety of the implanted device developed by InVivo Therapeutics Holdings Corp. If proven successful, surgeons believe the new technique could become a standard protocol in the treatment of acute spinal cord injury.
